The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | MRD measurement as a strategy for treatment-free survival
Ola Landgren
• 14 Jun 2018
Could patients who remain MRD negative long-term whilst on maintenance treatment cease treatment? Here, Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, discusses the utilization of MRD measurement as a strategy for treatment-free survival. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
